Iambic Therapeutics, Inc. (IAM)
NASDAQ
Closed
Oct 20, 2026
Day's Range
15.0052 wk Range
14.10Overview - IAM - Iambic Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
637.76M
Price / Sales (TTM)
‪49.11‬
EV / EBITDA
‪-6.45‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-419.59%‬
Ownership
Shares Outstanding
47.40M
Float
4.17M
Market Cap - IAM - Iambic Therapeutics, Inc.
Peers - IAM - Iambic Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- IAMNASDAQIambic Therapeutics, Inc.1.12BMarket Cap+20.58%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.03BMarket Cap-23.08%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.82BMarket Cap+8.90%52-week change17.26P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - IAM - Iambic Therapeutics, Inc.
About
Iambic Therapeutics, Inc. is a clinical-stage biotechnology and life sciences company developing small-molecule medicines through an AI-driven drug discovery platform. Its molecular superintelligence approach combines proprietary artificial intelligence with automated, scalable chemistry and biology experiments to…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
